Clinical Trials Browser

Not yet recruiting × INDUSTRY × Paclitaxel × Clear all

NCT07545460 2026-04-22

A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Phase 3 Not yet recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT07524257 2026-04-13

ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07518147 2026-04-08

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

Phase 3 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT07492680 2026-03-25

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Phase 2 Not yet recruiting

CNSDermatologicGastrointestinal

Brain Neoplasms, Melanoma, Pancreatic Neoplasms

NCT07286266 2026-03-19

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

Phase 3 Not yet recruiting

Ovarian Neoplasms

NCT07472647 2026-03-16

SYS6090 Combination Therapy in Advanced Lung Cancer

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT07465757 2026-03-12

ALISCA-Lung2

Phase 2 Not yet recruiting

Small Cell Lung Carcinoma

NCT07286331 2026-03-11

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)

Phase 3 Not yet recruiting

Endometrial Neoplasms

NCT07463573 2026-03-11

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Phase 3 Not yet recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07360132 2026-01-22

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Phase 3 Not yet recruiting

Squamous Non-small Cell Lung Cancer

NCT07298772 2025-12-23

A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT07262567 2025-12-03

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

Phase 3 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06835400 2025-07-11

Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer

Phase 3 Not yet recruiting

Breast Neoplasms

NCT06867562 2025-03-10

Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer

Phase 3 Not yet recruiting

Platinum-Resistant Primary Peritoneal Carcinoma

NCT06751485 2024-12-31

JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer

Phase 3 Not yet recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06682611 2024-11-12

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

Phase 1/2 Not yet recruiting

Other solid neoplasm

Unresectable Locally Advanced or Metastatic Solid Tumors

NCT06662669 2024-10-29

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

Phase 1/2 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06620029 2024-10-01

BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer

Phase 1/2 Not yet recruiting

Ovarian Neoplasms, Endometrial Neoplasms

NCT05990127 2023-08-14

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05794659 2023-07-20

Cornerstone4

Phase 2 Not yet recruiting

Advanced Ovarian Cancer

NCT05798819 2023-04-05

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 3 Not yet recruiting

Recurrence

NCT05715840 2023-02-08

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

Phase 3 Not yet recruiting

Recurrence